Philip Cohen, of Dundee University to Speak at Protein Kinases Conf, May 8-9, 2014, Berlin, DEU

Monrovia, CA, November 28, 2013 --(PR.com)-- Sir Philip Cohen, Co-Director of the Division of Signal Transduction Therapy and Professor of Enzymology at Dundee University will give the keynote presentation at the Protein Kinases in Drug Discovery Conference to be held in Berlin, Germany on May 8-9, 2014 by GTC.

His lab has recently identified several mechanisms that prevent the MyD88 signaling network from being activated too strongly. They therefore prevent the overproduction of inflammatory mediators and hence the on-set of autoimmune disease. Research showed that the IKK-related kinases, TBK1 and IKKε phosphorylate and inhibit the canonical IKK-complex to prevent the hyper-activation of NFκB. The lab also discovered that the interaction of ubiquitin chains with ABIN1 restricts the activation of the MyD88 signaling network and prevents the development of lupus.

The Protein Kinases in Drug Discovery Conference is a premier conference that hosts an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities, and will focus on drug discovery aspects within the kinase field. A balance of both academic and industry experts will facilitate discussion on validation of novel kinase targets, kinase inhibitor development, lessons from preclinical models and clinical development, and selectivity and off pathway toxicity.

This conference is part of the European Drug Discovery Summit 2014, which consists of the following co-located conferences:

1) Tissue Models & Drug Screening
2) Cancer Drug Research & Development
3) Drug Design & Medicinal Chemistry
4) Protein Kinases in Drug Discovery

For more information, please visit www.gtcbio.com/PKDD_E